Feb 21,2018

Cota Raises $40M in Series C Financing

Cota, Inc., a NYC-based healthcare real-world evidence and data analytics company, completed a $40M Series C round of financing. The round was led by IQVIA (NYSE: IQV) with participation from EW Healthcare Partners, Memorial Sloan Kettering Cancer Center and existing investors Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings. With its participation in the Series C round, IQVIA has secured a seat on Cota�s board of directors. The company intends to use the funds to scale its solutions across healthcare providers, payers and life sciences companies.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Mar 20,2018

Cancer-Fighting Startup Tempus Raises $80M in New Funding

Tempus, a Chicago startup led by Groupon co-founder Eric Lefkofsky, raised $80 million in a new funding round Tuesday, bringing the company's total amount raised to $210 million. Investors in the startup's latest round include new backers Kinship Trust Company and T. Rowe Price, along with existing investors New Enterprise Associates and Revolution Growth.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Mar 23,2018

DermaSensor has raised $3.1M

DermaSensor, a medical device company that specializes in skin cancer detection, has raised $3.1 million USD through a private offering of securities.

FUNDING CONVERTIBLE NOTE
View Analyst & Ambassador Comments
Go to original news
Mar 28,2018

LetsGetChecked Raises $12M to Bring Personal Health Tests Into the Homes of Millions

LetsGetChecked, the medical health testing platform that allows customers to access regulated laboratory testing and self-test from the comfort of home, today announces the closing of $12 million in Series A funding. Led by Optum Ventures, the independent venture fund of health services leader Optum, and Qiming Venture Partners, a leading Chinese venture capital firm, the funding will be used to scale the company, fuel development of the technology platform linking customers to laboratories, and grow the full clinical support team.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 19,2018

BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation

BenevolventAI announced today that it has raised $115 million to continue developing its core �AI brain� as well as different arms of the company that are using it specifically to break new ground in drug development and more. This venture round values the company at $2.1 billion post-money.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
May 23,2018

OWKIN Scores Additional Financing

OWKIN, the AI startup that uses machine learning to augment medical and biology research, today announced it has closed an additional Series A investment round extension with GV, raising a total of $18 million to-date. The capital raised will be used to continue the development of its AI platform, strengthen the company's strategic partnerships, and support internal growth.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jun 18,2018

Insilico Medicine has raised $6M

Insilico Medicine has raised $6 million USD through a private offering of securities for its artificial intelligence-based drug discovery and aging research, according to the SEC form registered by the company.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 30,2018

SkinVision gets $7.6M to continue expanding skin cancer app

Amsterdam-based skin cancer screening app SkinVision has raised $7.6 million in new funding from existing investors Leo Pharma and PHS Fund, with additional contributions from undisclosed new backers described by the company as "high net worth impact investors." This is the second major funding raise for the company, which launched in 2012 under the name Skin Scan, after a $3.4 million round in 2015. It also received some additional funding from Leo in 2017. The company's total funding stands at $13 million.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Aug 29,2018

Tempus raises $110M Series E, pushing valuation past $2B

On Wednesday, Tempus announced it has raised a $110 million Series E, which pushes its total funding to $320 million and its valuation to over $2 billion. Participants in the round include existing investors Revolution Growth, New Enterprise Associates and T. Rowe Price, as well as one newcomer, British investment management firm Baillie Gifford. The company has partnered with the American Society of Clinical Oncologists, academic medical centers, National Cancer Institute-designated cancer research centers, hospital networks and local physicians across the country to build the world�s largest library of clinical and molecular cancer data.

FUNDING SERIES E
View Analyst & Ambassador Comments
Go to original news
Oct 24,2018

Cancer diagnostic inventions receive £3.8 million backing

C the Signs, Cambridge Oncometrix, Chromition and Deep Med IO have all received the funding from SBRI Healthcare after initially being awarded £100,000 each after winning a national competition - meaning they can now be fast-tracked to market. The further investment follows the companies demonstrating technical feasibility over a six-month development phase.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING